A Phase I, Open-Label Drug-Drug Interaction Trial to Investigate the Effect of TMC278 25 mg q.d. on the Steady State Pharmacokinetics of Ethinylestradiol and Norethindrone, in Healthy Women.
Phase of Trial: Phase I
Latest Information Update: 28 Oct 2013
At a glance
- Drugs Rilpivirine (Primary) ; Ethinylestradiol/norethisterone
- Indications HIV-1 infections; Pregnancy
- Focus Pharmacokinetics
- Sponsors Janssen R&D Ireland
- 10 Jun 2017 Biomarkers information updated
- 29 Jan 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
- 29 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.